Synthes Delivers Solid Q1 2011 Sales Growth of 8% (6% in local currency)

West Chester (PA), USA, April 28, 2011

Synthes (SIX: SYST.VX) today announced its First Quarter 2011 sales results.

• Global revenue increased 7.8% (6.0% in local currency [LC]) vs. PY to U.S.$ 983.0 million, including revenue from Anspach.
• Asia Pacific generated exceptional results, delivering double-digit growth in Japan, and growth exceeding 20% in almost every other market, including Australia, China and India.
• Global Trauma sales growth, fueled by new product launches and targeted field initiatives, remained solid despite the impact of a mild winter in 2011 vs. a strong winter in Q1 of 2010 in Europe.
• Challenging market dynamics continued to impact performance in Spine, particularly in the U.S., where payors increased restrictions on reimbursement for lumbar fusions. New product launches in the lumbar fixation and inter-vertebral body spacer segments in North America and the cervical segment in Europe and Asia Pacific offset some of the market challenges.
• Matrix (a comprehensive pedicle screw system for lumbar spine surgery launched in Q4 2010) has exceeded expectations in the U.S., with more than 90% of Matrix procedures performed by surgeons who had not previously used Synthes’ products. A successful global Matrix launch remains Synthes’ top priority, as the company will also introduce the system in Europe in Q2 2011.
• CMF expanded its product and service offering by finalizing an exclusive partnership with Materialise. The alliance will provide surgeons with a cutting-edge software service to reduce complexity in the operating room and improve patient care in core facial markets.

Michel Orsinger, President and CEO of Synthes, commented on the performance:
“Synthes is off to a solid start in 2011, especially considering the strong 2010 sales base and the challenging market environment. We have successfully launched new products and are committed to gaining market share by focusing on strong execution of further product launches, particularly the Forefoot/Midfoot System in Trauma and Matrix in Spine, as well as on continuous investments in emerging markets.”

full article

Tags: Michel Orsinger, synthes

Category: Financial News, News